- Home
- NMTC vs MTVA Comparison
NMTC vs MTVA Comparison
Compare NMTC & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMTC
- MTVA
- Stock Information
- Founded
- NMTC 2009
- MTVA 2014
- Country
- NMTC United States
- MTVA United States
- Employees
- NMTC N/A
- MTVA N/A
- Industry
- NMTC Medical/Dental Instruments
- MTVA
- Sector
- NMTC Health Care
- MTVA
- Exchange
- NMTC Nasdaq
- MTVA NYSE
- Market Cap
- NMTC 14.8M
- MTVA 13.6M
- IPO Year
- NMTC N/A
- MTVA N/A
- Fundamental
- Price
- NMTC $0.59
- MTVA $0.81
- Analyst Decision
- NMTC
- MTVA Strong Buy
- Analyst Count
- NMTC 0
- MTVA 1
- Target Price
- NMTC N/A
- MTVA $12.00
- AVG Volume (30 Days)
- NMTC 453.4K
- MTVA 1.4M
- Earning Date
- NMTC 05-13-2025
- MTVA 05-08-2025
- Dividend Yield
- NMTC N/A
- MTVA N/A
- EPS Growth
- NMTC N/A
- MTVA N/A
- EPS
- NMTC N/A
- MTVA N/A
- Revenue
- NMTC $5,749,521.00
- MTVA N/A
- Revenue This Year
- NMTC $292.88
- MTVA N/A
- Revenue Next Year
- NMTC N/A
- MTVA N/A
- P/E Ratio
- NMTC N/A
- MTVA N/A
- Revenue Growth
- NMTC 104.21
- MTVA N/A
- 52 Week Low
- NMTC $0.40
- MTVA $0.71
- 52 Week High
- NMTC $1.39
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- NMTC 39.84
- MTVA N/A
- Support Level
- NMTC $0.54
- MTVA N/A
- Resistance Level
- NMTC $0.61
- MTVA N/A
- Average True Range (ATR)
- NMTC 0.06
- MTVA 0.00
- MACD
- NMTC 0.01
- MTVA 0.00
- Stochastic Oscillator
- NMTC 37.82
- MTVA 0.00
About NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.